Greg J. Santora Sells 7,700 Shares of Align Technology, Inc. (ALGN) Stock
Align Technology, Inc. (NASDAQ:ALGN) Director Greg J. Santora sold 7,700 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $238.95, for a total value of $1,839,915.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The company had revenue of $385.30 million during the quarter, compared to the consensus estimate of $359.80 million. During the same period last year, the business posted $0.63 earnings per share. Align Technology’s revenue was up 38.3% on a year-over-year basis.
A number of large investors have recently added to or reduced their stakes in ALGN. Schroder Investment Management Group purchased a new stake in Align Technology in the second quarter worth $104,000. CENTRAL TRUST Co increased its position in Align Technology by 128.5% in the second quarter. CENTRAL TRUST Co now owns 697 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 392 shares during the last quarter. Whittier Trust Co. purchased a new stake in Align Technology in the third quarter worth $107,000. Bronfman E.L. Rothschild L.P. increased its position in Align Technology by 13.0% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 912 shares of the medical equipment provider’s stock worth $137,000 after buying an additional 105 shares during the last quarter. Finally, BlueMountain Capital Management LLC purchased a new stake in Align Technology in the second quarter worth $148,000. 80.96% of the stock is owned by institutional investors and hedge funds.
Several research analysts have weighed in on ALGN shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $176.00 price target on shares of Align Technology in a research report on Friday, July 28th. Robert W. Baird reaffirmed a “buy” rating and set a $245.00 price target on shares of Align Technology in a research report on Friday, October 27th. Leerink Swann reaffirmed an “outperform” rating and set a $250.00 price target on shares of Align Technology in a research report on Friday, October 27th. Morgan Stanley reaffirmed an “overweight” rating and set a $182.00 price target (up previously from $175.00) on shares of Align Technology in a research report on Monday, July 17th. Finally, Stifel Nicolaus boosted their price target on Align Technology from $205.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Eleven equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $214.45.
About Align Technology
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.